Effect of probiotics during vonoprazan-containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial.
Adolescent
Amoxicillin
/ therapeutic use
Anti-Bacterial Agents
/ therapeutic use
Clarithromycin
/ therapeutic use
Diarrhea
/ drug therapy
Drug Therapy, Combination
Female
Gastrointestinal Microbiome
/ drug effects
Helicobacter Infections
/ drug therapy
Helicobacter pylori
/ drug effects
Humans
Male
Probiotics
/ therapeutic use
Pyrroles
/ therapeutic use
Sulfonamides
/ therapeutic use
Helicobacter pylori
Biofermin-R
gut microbiota
vonoprazan
Journal
Helicobacter
ISSN: 1523-5378
Titre abrégé: Helicobacter
Pays: England
ID NLM: 9605411
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
15
01
2020
revised:
11
02
2020
accepted:
28
02
2020
pubmed:
25
3
2020
medline:
4
11
2020
entrez:
25
3
2020
Statut:
ppublish
Résumé
Probiotics are beneficial to patients with Helicobacter pylori infections by modulating the gut microbiota. Biofermin-R (BFR) is a multiple antibiotic-resistant lactic acid bacteria preparation of Enterococcus faecium 129 BIO 3B-R and is effective in normalizing the gut microbiota when used in combination with antibiotics. This study aimed to determine the effect of BFR in combination with vonoprazan (VPZ)-based therapy on gut microbiota. Patients with positive urinary anti-H pylori antibody test (primary test) and fecal H pylori antigen test (secondary test) were examined. Patients in group 1 (BFR Supplementation with BFR prevented the decrease in a-diversity after eradication therapy (Day 7). β-diversity was similar between groups. The incidence rate of diarrhea was non-significantly higher in the BFR Biofermin-R combined with VPZ-based therapy resulted in higher microbial α-strain diversity and suppressed stool softening during H pylori eradication therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Probiotics are beneficial to patients with Helicobacter pylori infections by modulating the gut microbiota. Biofermin-R (BFR) is a multiple antibiotic-resistant lactic acid bacteria preparation of Enterococcus faecium 129 BIO 3B-R and is effective in normalizing the gut microbiota when used in combination with antibiotics. This study aimed to determine the effect of BFR in combination with vonoprazan (VPZ)-based therapy on gut microbiota.
METHODS
METHODS
Patients with positive urinary anti-H pylori antibody test (primary test) and fecal H pylori antigen test (secondary test) were examined. Patients in group 1 (BFR
RESULTS
RESULTS
Supplementation with BFR prevented the decrease in a-diversity after eradication therapy (Day 7). β-diversity was similar between groups. The incidence rate of diarrhea was non-significantly higher in the BFR
CONCLUSION
CONCLUSIONS
Biofermin-R combined with VPZ-based therapy resulted in higher microbial α-strain diversity and suppressed stool softening during H pylori eradication therapy.
Substances chimiques
1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine
0
Anti-Bacterial Agents
0
Pyrroles
0
Sulfonamides
0
Amoxicillin
804826J2HU
Clarithromycin
H1250JIK0A
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12690Subventions
Organisme : Biofermin Pharmaceutical Co., Ltd.
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Brown LM. Helicobacter pylori epidemiology and routes of transmission. Epidemiol Rev. 2000;22:283-297.
Cheng H, Hu F, Zhang L, et al. Prevalence of Helicobacter pylori infection and identification of risk factors in rural and urban Beijing. China. Helicobacter. 2009;14:128-133.
Asaka M, Kato M, Takahashi S, et al. Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009. Helicobacter. 2010;15:1-20.
Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: Evidence-based medicine rather than medicine-based evidence (revision 2). Clin Gastroenterol Hepatol. 2014;12(177-86):e3.
Kobayashi I, Murakami K, Kato M, et al. The current prevalence of drug-resistant Helicobacter pylori in Japan-a summary of 2006 surveillance of resistant bacteria and a 5-year summary. J Japan Soc Helicobacter Res. 2009;10:98-103.
Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339:412-420.
Sugimoto M, Yamaoka Y. Role of Vonoprazan in Helicobacter pylori eradication therapy in Japan. Front Pharmacol. 2019;9:1560.
Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46:106-114.
Otsuka T, Sugimoto M, Inoue R, et al. Influence of potassium-competitive acid blocker on the gut microbiome of Helicobacter pylori-negative healthy individuals. Gut. 2017;66:1723-1725.
Lv Z, Wang B, Zhou X, et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis. Exp Ther Med. 2015;9:707-716.
Çekin AH, Şahintürk Y, Akbay Harmandar F, et al. Use of probiotics as an adjuvant to sequential H pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance. Turk J Gastroenterol. 2017;28:3-11.
Yamashita M, Hatano M, Nakamura H, et al. Effects of Biofermin-R administered in combination with antibiotics on the fecal flora. Bifidobacteria Microflora. 1985;4:23-30.
Oh B, Kim BS, Kim JW, et al. The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial. Helicobacter. 2016;21(3):165-174.
Rizzatti G, Gianluca I, Gasbarrini A. Antibiotics and modulation of microbiota. A new paradigm? J Clin Gastroenterol. 2018;52:S74-S77.
Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut. 2016;65:1906-1915.
Korpela K, Salonen A, Virta LJ, et al. Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. Nat Commun. 2016;7:10410.
Willmann M, El-Hadidi M, Huson DH, et al. Antibiotic selection pressure determination through sequence-based metagenomics. Antimicrob Agents Chemother. 2015;59:7335-7345.
Chen L, Xu W, Lee A, et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: An open-label, randomized clinical trial. EBioMedicine. 2018;35:87-96.
Cornejo-Pareja I, Martín-Núñez GM, Roca-Rodríguez MM, et al. pylori eradication treatment alters gut microbiota and GLP-1 secretion in humans. J Clin Med. 2019;8:451.
Gao JJ, Zhang Y, Gerhard M, et al. Association between gut microbiota and Helicobacter pylori-related gastric lesions in a high-risk population of gastric cancer. Front Cell Infect Microbiol. 2018;8:202.
Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220-230.
Myllyluoma E, Ahlroos T, Veijola L, et al. Effects of anti-Helicobacter pylori treatment and probiotic supplementation on intestinal microbiota. Int J Antimicrob Agents. 2007;29:66-72.
Blaabjerg S, Artzi DM, Aabenhus R. Probiotics for the prevention of antibiotic-associated diarrhea in outpatients-A systematic review and meta-analysis. Antibiotics (Basel). 2017;6:21.
Vandeputte D, Falony G, Vieira-Silva S, et al. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016;65:57-62.